PuSH - Publikationsserver des Helmholtz Zentrums München

Zeitschriften-Browsing

63 Datensätze gefunden.
Zum Exportieren der Ergebnisse bitte einloggen.
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮
Alle Publikationen dieser Seite in den Korb legen
41.
Wurster, S.* et al.: PARP1 inhibition radiosensitizes HNSCC cells deficient in homologous recombination by disabling the DNA replication fork elongation response. Oncotarget 7, 9732-9741 (2016)
42.
Falkenberg, N. et al.: Secreted uPAR isoform 2 (uPAR7b) is a novel direct target of miR-221. Oncotarget 6, 8103-8114 (2015)
43.
Jacobi, C.* et al.: Potential impact of human papilloma virus on survival of basaloid squamous carcinoma of the head and neck. Oncotarget 6, 3462-3470 (2015)
44.
Leinhäuser, I. et al.: Oncogenic features of the Bone Morphogenic Protein 7 (BMP7) in pheochromocytoma. Oncotarget 6, 39111-39126 (2015)
45.
Mancuso, M.* et al.: Acceleration of atherogenesis in ApoE-/- mice exposed to acute or low-dose-rate ionizing radiation. Oncotarget 6, 31263-31271 (2015)
46.
Nagel, D. et al.: Combinatorial BTK and MALT1 inhibition augments killing of CD79 mutant diffuse large B cell lymphoma. Oncotarget 6, 42232-42242 (2015)
47.
Ribi, S.* et al.: TP53 intron 1 hotspot rearrangements are specific to sporadic osteosarcoma and can cause Li-Fraumeni syndrome. Oncotarget 6, 7727-7740 (2015)
48.
Teiluf, K.* et al.: α-Radioimmunotherapy with 213Bi-anti-CD38 immunoconjugates is effective in a mouse model of human multiple myeloma. Oncotarget 6, 4692-4703 (2015)
49.
Walsh, K.M.* et al.: Longer genotypically-estimated leukocyte telomere length is associated with increased adult glioma risk. Oncotarget 6, 42468-42477 (2015)
50.
Xie, B.* et al.: Necrosis avid near infrared fluorescent cyanines for imaging cell death and their use to monitor therapeutic efficacy in mouse tumor models. Oncotarget 6, 39036-39049 (2015)
51.
Zhang, S.* et al.: Anti-leukemic effects of the V-ATPase inhibitor Archazolid A. Oncotarget 6, 43508-43528 (2015)
52.
Aichler, M. et al.: Epidermal Growth Factor Receptor (EGFR) is an independent adverse prognostic factor in esophageal adenocarcinoma patients treated with cisplatin-based neoadjuvant chemotherapy. Oncotarget 5, 6620-6632 (2014)
53.
Alachkar, H.* et al.: Preclinical efficacy of Maternal Embryonic Leucine-zipper Kinase (MELK) inhibition in acute myeloid leukemia. Oncotarget 5, 12371-12382 (2014)
54.
Bedi, U.* ; Kumar Mishra, V.* ; Wasilewski, D. ; Scheel, C. & Johnsen, S.A.*: Epigenetic plasticity: A central regulator of epithelial-tomesenchymal transition in cancer. Oncotarget 5, 2016-2029 (2014)
55.
Keitel, U.* et al.: Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation. Oncotarget 5, 11778-11791 (2014)
56.
Litzenburger, U.M.* et al.: Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR. Oncotarget 5, 1038-1051 (2014)
57.
Neumann, M.* et al.: Mutational spectrum of adult T-ALL. Oncotarget 6, 2754-2766 (2014)
58.
Willimsky, G.* ; Protzer, U. ; Knolle, P.* & Heikenwälder, M.: Adoptive T-cell therapy to treat liver cancer: Is the liver microenvironment key? Oncotarget 4, 1117-1118 (2013)
59.
Hoos, A.* ; Wolf, M.J.* ; Bauer, J. ; Borsig, L.* & Heikenwälder, M.: Endothelial chemokine receptors as facilitators of tumor cell extravasation? Oncotarget 3, 919-920 (2012)
60.
Krappmann, D.: Attacking MALT1 for ABC-DLBCL therapy. Oncotarget 3, 1489-1490 (2012)
▮◀ ◀◀ 1 ... 2 ... 3 ... 4 ... ▶▶ ▶▮